Differential regulation of dopamine receptors after chronic typical and a typical antipsychotic drug treatment

Neuroscience

Volumn 78, Issue 4, 1997, Pages 985-996

  Tarazi, F I ^a,b   Florijn, W J ^a,c   Creese, I ^a  

^a RUTGERS UNIVERSITY   (United States)

^b MCLEAN HOSPITAL   (United States)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

atypical antipsychotics; autoradiography; chronic treatment; dopamine receptors; schizophrenia; typical antipsychotics

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CLOZAPINE; DOPAMINE RECEPTOR; EMONAPRIDE; HALOPERIDOL; NEUROLEPTIC AGENT; RACLOPRIDE; SPIPERONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; DOPAMINE BLOOD LEVEL; NONHUMAN; PRIORITY JOURNAL; PSYCHOSIS; RAT; RECEPTOR AFFINITY; SCHIZOPHRENIA; TREATMENT PLANNING;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; ANTIPSYCHOTIC AGENTS; AUTORADIOGRAPHY; CLOZAPINE; DOPAMINE ANTAGONISTS; HALOPERIDOL; MALE; RACLOPRIDE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SALICYLAMIDES; TIME FACTORS;

EID: 0030943566     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(96)00631-8     Document Type: Article

References (68)

1. Albin R. L., Young A. B. and Penney J. B. (1989) The functional anatomy of basal ganglia disorders. Trends Neurosci. 12, 366-375.
2. Alexander G. E. and Crutcher M. D. (1990) Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 13, 266-271.
3. 1 antagonists. Naunyn-Schmiedeberg's Arch. Pharmac. 338, 162-168.
4. 2) receptor binding in the frontal cortex of schizophrenic patients. J. neural Transm. 85, 19-29.
5. Baldessarini R. J. and Tarazi F. I. (1996) Brain dopamine receptors: a primer on their current status, basic and clinical. Harvard Rev. Psychiatry 3, 301-325.
6. Berger B., Gaspar P. and Verney C. (1991) Dopaminergic innervation of the cerebral cortex: unexpected differences between rodents and primates. Trends Neurosci. 14, 21-27.
7. Burt D. R., Creese I. and Snyder S. H. (1977) Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding. Science 196, 326-328.
8. 2 (haloperidol) antagonists in drug-naive monkeys. Psychopharmacology 107, 18-22.
9. 4 dopamine receptor-mediated signaling events determined in transfected chinese hamster ovary cells. J. biol. Chem. 269, 11,813-11,819.
10. Civelli O., Bunzow J. R. and Grandy D. K. (1993) Molecular diversity of the dopamine receptors. A. Rev. Pharmac. Toxic. 32, 281-307.
11. 1 receptors. J. Pharmac. exp. Ther. 249, 769-776.
12. 2 receptor blocker, in acute schizophrenia: an open trial. Int. Clin. Psychopharmac. 4, 61-70.
13. Creese I., Burt D. R. and Snyder S. H. (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192, 481-483.
14. Creese I., Burt D. R. and Snyder S. H. (1977) Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity. Science 197, 596-598.
15. 1 dopamine receptor increase following chronic treatment with SCH23390. Eur. J. Pharmac. 5, 107-110.
16. 2 dopamine mRNAs: ontogenetic and pharmacological studies. Neurochem. Int. 20, 45S-48S.
17. 3H]-Spiroperidol labels serotonin receptors in rat cerebral cortex and hippocampus. Eur. J. Pharmac. 49, 201-202.
18. 1 dopamine receptors in the rat brain: a quantitative autoradiographic analysis. J. Neurosci. 6, 2352-2365.
19. 2 receptors in the effects of classical neuroleptic haloperidol and the atypical neuroleptic clozapine. Eur. J. Pharmac. 196, 103-108.
20. 11C]raclopride. Psychopharmacology 107, 23-29.
21. 2-dopamine receptor occupancy by PET. Psychopharmacology 94, 1-7.
22. 2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology 99, S28-S31.
23. 11C]raclopride. Archs gen. Psychiat. 47, 213-219.
24. Florijn W. J. and Tarazi F. I. and Creese I. (1997) Dopamine receptor subtypes: differential regulation following 8 months treatment. J. Phamacol. Exp. Ther. 280, 561-569.
25. 4 receptor binding using antisense oligonucleotides. Soc. Neurosci. Abstr. 20, 909.
26. 1 receptor antagonist (NNC-756). Eur. J. Pharmac. 242, 283-291.
27. 3 receptors. Eur. J. Pharmac. 272, R1-R3.
28. 1 dopamine receptor upregulation. J. Pharmac. exp. Ther. 238, 846-854.
29. 1 receptor antagonism in schizophrenia: is there a reduced risk of extrapyramidal side-effects?. Trends pharmac. Sci. 11, 406-410.
30. 2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography. Archs gen. Psychiat. 51, 116-123.
31. 3H]-spiperone binding sites in various areas of the rat limbic system. Molec. Pharmac. 15, 506-514.
32. 2 receptors in the rat brain. Biochem. Pharmac. 34, 2251-2255.
33. 3H]raclopride. Neurosci. Lett. 66, 85-90.
34. 4 receptors in rat frontal cortex. J. neural Transm. 101, 231-235.
35. 2-Family receptor distribution in human post mortem tissue: an autoradiographic study. NeuroReport 6, 2505-2512.
36. 3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc. natn. Acad. Sci. U.S.A. 89, 8155-8159.
37. 3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons. Proc. natn. Acad. Sci. U.S.A. 92, 1719-1723.
38. 2-dopaminergic receptors in the primate cerebral cortex. Proc. natn. Acad. Sci. U.S.A. 91, 4353-4356.
39. 5 dopamine receptor mRNA in rat brain. Neurosci. Lett. 145, 209-212.
40. 4 dopamine receptors in post mortem striatum from patients with schizophrenia. J. Neurosci. 15, 2186-2191.
41. O'Dell S. J., La Hoste G. J., Widmark C. B., Shapiro R. M., Potkin S. G. and Marshall J. F. (1990) Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain. Synapse 6, 146-153.
42. 3H]Spiperone binding sites in brain: autoradiographic localization of multiple receptors. Brain Res. 213, 277-289.
43. 1 dopamine receptors. Eur. J. Pharmac. 118, 367-371.
44. 4 receptors increased in schizophrenia? J. Neurochem. 63, 1576-1577.
45. 4 receptors in drug-treated schizophrenia. Eur. J. Pharmac. 281, R5-R6.
46. 2 receptor function in the rat. Biochem. Pharmac. 34, 2755-2763.
47. 4 receptors by 2-fold in rats. Eur. J. Pharmac. 289, 67-72.
48. See R. E., Toga A. W. and Ellison G. (1990) Autoradiographic analysis of regional alterations in brain receptors following chronic administration and withdrawal of typical and atypical neuroleptics in rats. J. neural Transm. 82, 93-109.
49. Seeman P. (1980) Brain dopamine receptors. Pharmac. Rev. 32, 229-313.
50. 4. Neuropsychopharmacology 7, 261-285.
51. 4 receptors elevated in schizophrenia. Nature 365, 441-445.
52. 125I]epidepride. Eur. J. Pharmac. 286, R3-R5.
53. Seeman P., Lee T., Chau-Wong M. and Wong K. (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261, 717-719.
54. 3H]nemonapride. J. Neurochem. 64, 1413-1415.
55. 1 binding site correlates of haloperidol-induced oral dyskinesia in rat. Expl Neurol. 127, 62-69.
56. Sibley D. R. and Monsma F. J. (1992) Molecular biology of dopamine receptors. Trends pharmac. Sci. 13, 61-69.
57. 2 receptor. Eur. J. Pharmac. 225, 331-337.
58. 3) as a target for neuroleptics. Nature 347, 146-151.
59. 3H]raclopride binding in post mortem caudate nucleus of subjects with schizophrenia or major depression. Brain Res. 681, 109-116.
60. 4 receptor. Neurosci. Lett. 199, 69-72.
61. 1. Nature 350, 610-614.
62. 4 dopamine receptors. Soc. Neurosci. Abstr. 22, 830.
63. 2 receptor. Trends pharmac. Sci. 10, 74-77.
64. 2 dopamine receptor mRNA levels. Neurosci. Lett. 111, 303-308.
65. 4 receptor gene with high affinity for the antipsychotic clozapine. Nature 350, 614-619.
66. 2) receptors in the rat brain. Brain Res. 487, 288-298.
67. 2 dopamine receptors in drug-naive schizophrenics. Science 234, 1558-1563.
68. 2 receptor group, in the rat brain and spinal cord. J. comp. Neurol. 344, 121-136.